Read the latest issue of Drug Discovery World The DDW Spring issue explores the breakthroughs occurring in Huntington’s disease, looks at the challenges facing endometriosis drug development and highlights how quantum computing can advance drug discovery research. Other features in the Spring issue include: - A market report on the US biotech hubs driving drug discovery - The unmet need for fibrosis treatments and emerging treatment opportunities - AI and the future of cell therapies Read the digital version here. https://lnkd.in/eXZHkKp9 #DrugDiscovery #AI #CellTherapy
Drug Discovery World
Book and Periodical Publishing
The Global Business Review of Drug Discovery and Development
About us
Welcome to our LinkedIn page. This is where we will share original content from the DDW team and industry experts, as well as daily news and other company updates. Published for over 20 years, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry Gurus’ to discuss and encourage debate on some of the more challenging issues surrounding the technological, strategic and business facets of the pharma and biopharmaceutical industry. DDW has always adhered to the maxim….’Turning Science into Business’. DDW examines the advances in new science and technology with a view to the commercial implications of implementing those advances and whether they can truly bring benefits to the drug discovery and development process with the goal of reducing costs and attrition rates whilst ultimately, bringing new and effective therapeutics to the market faster. DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level allowing them to understand the new technologies and strategies and the impact they can have on their particular segments of the business. Scientist and CEO alike can profit from the uncomplicated style of the editorial and, furthermore, gain a wealth of information on a diverse range of life science topics. In our articles, we challenge the industry to look at new ways of overcoming discovery bottlenecks, embrace new technologies, form relationships with discovery partners and build next generation technology platforms.
- Website
-
https://www.ddw-online.com/
External link for Drug Discovery World
- Industry
- Book and Periodical Publishing
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2000
- Specialties
- Drug Discovery, Pharmaceuticals, Publishing, Biotechnology, and Biopharmaceutical
Locations
-
Primary
Get directions
London, GB
Employees at Drug Discovery World
Updates
-
'Turning Science into Business' AI & ML summit: Navigating AI-driven drug discovery Hosted by Drug Discovery World and sponsored by The Jackson Laboratory, register now for the DDW ‘Turning Science into Business’ AI & ML summit: Navigating AI-driven drug discovery, to learn about the areas of opportunity for AI & ML in the drug discovery sector. Taking place on 30 April, 7am PDT / 10am EDT / 3pm BST / 4pm CEST, the DDW ‘Turning Science into Business’ AI & ML summit will see experts and thought leaders in AI describe the latest research and applications that are driving the drug discovery process. You will hear from Mark Hammond, Founding Director at Deep Science Ventures, Yochi Slonim, Co-founder and CEO of Anima Biotech, and V. Tyrone Lam, Chief Operating Officer, at GATC Health. There will also be a panel discussion which will explore the areas of opportunity and where AI can be used to address unmet needs in drug discovery, as well as the future opportunities AI & ML present for drug discovery and development. Wed, Apr 30, 2025 3:00 PM - 4:00 PM BST Register for free now! https://lnkd.in/eBrTFMWw Sponsored by The Jackson Laboratory #DrugDiscovery #AI #LifeSciences
-
-
Podcast: Where is the innovation and opportunity in the therapeutic antibody market? This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases will benefit from therapeutic antibody development?” https://lnkd.in/g2jQ8MGr #TherapeuticAntibodies #DrugDiscovery #Antibodies
-
-
Transform Drug Discovery with Single Cell Precision Scale Bio’s ScalePlex technology and Single Cell RNA Sequencing Kit v1.1 are revolutionising drug discovery by making large-scale single cell sample and condition screening possible. - Libraries from 384 drug conditions were prepared in just 1.5 days - 90% reduction in processing time - >80% cell recovery rate and >3000 unique transcripts per cell Download App Note https://lnkd.in/gEaCgpqd Brought to you by Scale Biosciences #DrugDiscovery #SingleCellPrecision #RNA
-
-
Improving drug discovery with organoids and 3D biology Created by DDW and sponsored by SPT Labtech, ‘Improving drug discovery with organoids and 3D biology’ is a free In Focus report available to download now. This In Focus eReport highlights the latest breakthroughs shaping the future of drug discovery in this area. The eReport includes: - A global market overview of organoids and 3D biology - Unlocking the potential of CNS organoid models: an article in which Dr Bryan Vought shares his thoughts - Insight from SPT Labtech on how automation is advancing organoid and 3D biology models - New frontiers for organoids and 3D biology Download the e-report https://lnkd.in/gcFqdBvA #Organoids #3DBiology #Automation
-
-
The future direction and applications of flow cytometry Miguel Tam, Director of Strategic Marketing at Revvity’s BioLegend, explores the future directions and applications of flow cytometry in drug discovery, highlighting the opportunities it presents and the challenges that lie ahead Flow cytometry has long been a cornerstone in biomedical research and clinical diagnostics, offering unparalleled capabilities to analyse multiple parameters of single cells in a high-throughput manner. Its utility in drug discovery and development has steadily expanded, and as the landscape of therapeutic innovation evolves, so too does the potential of flow cytometry. https://lnkd.in/e5hCzija #FlowCytometry #DrugDiscovery #Biotech
-
-
AI identifies new product candidate for lupus Charles River Laboratories and Valo Health have announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications. https://lnkd.in/eBRhWydW #Lupus #AI #AutoimmuneDiseases
-
-
From the Editor: Science under threat https://lnkd.in/ey7Zih94 #LifeSciences #DrugDiscovery #Funding
-
-
Only a few days left to register for this webinar!
Ion channel drug discovery – current trends and future opportunities Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the last decade. The major drivers for choosing ion channel targets and specific therapeutic indications will be assessed, and examples provided of different ligand modalities applied to ion channels (small molecules, biologicals such as toxins and antibodies, and protein modulation pathways). Case studies will be provided to illustrate both successful projects and recent challenges for programs targeting voltage- and ligand-gated ion channels in the periphery and CNS for a variety of both common and rare cardiac, musculo-skeletal, respiratory, renal, ophthalmological, pain, epilepsy and neuropsychiatric diseases. You will learn: • Why ion channels are important and tractable drug discovery targets • Recent, current, and future ion channel targets and their therapeutic indications, including the latest high impact work on organellar ion channels • Strengths and weaknesses of different drug discovery modalities targeting ion channels (small molecules, biologicals, protein modulation pathways) Wed, Apr 9, 2025 3:00 PM - 4:00 PM BST Register for free now to secure your place at the webinar! https://lnkd.in/eh5zjxGT Supported by Axxam #DrugDiscovery #DrugDevelopment #LifeSciences
-
-
ELRIG announces keynote speakers for Therapeutic Oligonucleotides 2025 ELRIG has announced that Professor Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, will provide the keynote talks at Therapeutic Oligonucleotides 2025. The event ‘Therapeutic Oligonucleotides 2025: Drugging the Undruggable’ will take place at AstraZeneca in Gothenburg, Sweden from 14-15 May 2025. https://lnkd.in/e8NxGCHk #ELRIG #DrugDiscovery #Oligonucleotides
-